Home / Intelligence / Webinars / 2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
Available On Demand
How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL?
As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.
In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss the role of the new value-based assessment framework in NRDL payer decision-making and dive into the nuances of 2023 NRDL pricing outcomes to inform manufacturer strategies in navigating the dynamic access and pricing landscape in China.
Key Webinar Topics:
- Overview of the 2023 China NRDL update: changes, trends and outcomes
- Case studies of oncology and rare disease drugs: takeaways from success and failure stories
- Recommendation and outlook for future NRDL updates
Featuring
Max Hunt
Partner,
Value, Access & Pricing
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Flora Chung
Engagement Manager,
Value, Access & Pricing
Rya Zhang
Consultant,
Value, Access & Pricing
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
May 21, 2025 | 1:00 – 1:45 PM ET
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Sign Up Now
Webinars
Health Equity in HTA Outcomes: Navigating the New Frontier
Available On Demand
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Watch Now
Webinars
Virtual Demo | HTA Vision with GenAI
Available On Demand
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities. It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future […]
Watch Now